Compare Gilead Sciences, Inc. (GILD) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Zoom Video Communications, Inc. — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Zoom Video Communications, Inc. trades at $97.74 (market cap $27.62B). The key difference: Gilead Sciences, Inc. is far larger — about 6.6× Zoom Video Communications, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Zoom Video Communications, Inc. for 92 Days on average.
| GILD | ZM | |
|---|---|---|
Market Cap | $182.40B | $27.62B |
Volume | 4,469,821 | 3,913,188 |
Sector | Health | Technology |
52-Week High | $155.80 | $111.88 |
52-Week Low | $117.18 | $72.72 |
Typical Hold Time | 111 Days | 92 Days |
Enterprise Value | $205.46B | $20.43B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
Zoom Communications (ZM) trades at $94.67, showing minimal daily movement (-0.11%). The stock maintains a bullish technical outlook with strong moving average signals, though oscillators indicate neutral momentum. Fundamentally, ZM demonstrates robust profitability with 77.3% gross margins and 65.19% net income margin, supported by recent earnings beats. The company continues to innovate with AI-powered revenue solutions and maintains significant institutional interest.
With a consensus price target of $118.08 offering 25% upside potential, ZM presents growth opportunities driven by AI integration and strong financial metrics. However, risks include competitive pressures in the communication software space and reliance on international sales growth. The mixed analyst sentiment (38.78% buy vs 55.1% hold) suggests cautious optimism amid solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
